Cardiopulmonary Disease Diagnostics Treatment Market

• Rising cardiovascular disease prevalence is driving the market growth

Market CAGR for cardiopulmonary disease diagnostics and treatment is driven by the growing prevalence of cardiovascular diseases. The increasing prevalence of chronic cardiovascular illnesses worldwide is a major driver of cardiopulmonary disease diagnostics and treatment in the  market. According to World Health Organisation, cardiovascular disease is the leading cause of mortality worldwide. ly, 17.9 million people die from cardiovascular disorders each year. High salt intake in the diet, increased tobacco use, increased smoking prevalence, and increased alcohol use are the main contributors to cardiovascular illnesses. By catching cardiovascular disorders early, they can be efficiently treated.

Therefore, the market for cardiopulmonary disease diagnostics and treatment is predicted to rise due to the increasing demand for early identification of cardiovascular disorders.

The rising number of persons with diabetes and obesity drives the market for cardiopulmonary disease diagnostics and treatment. Obesity is linked to risk factors like high blood pressure and high cholesterol, and diabetes increases the risk of cardiovascular illnesses. For instance, as per a study by American Heart Association (AMA), CVD cases will increase to 22.2 million by 2030. Another study by the American Medical Association (AMA) in the U.S. found that 26 million people have had diabetes diagnosed and that an additional 9 million people have the condition but have not yet received a diagnosis.

Thus, driving the cardiopulmonary disease diagnostics and treatment market revenue.

There is a notable increase in public awareness and education regarding cardiopulmonary diseases, which serves as a catalyst for the Global Cardiopulmonary Disease Diagnostics and Treatment Market Industry. Campaigns aimed at educating the public about risk factors, symptoms, and the importance of early diagnosis are becoming more prevalent. This heightened awareness encourages individuals to seek medical attention sooner, leading to increased demand for diagnostic services and treatment options. As a result, healthcare providers are likely to expand their offerings to meet this growing need, further propelling market growth.

Government initiatives aimed at improving healthcare infrastructure and funding for cardiopulmonary disease research are pivotal to the Global Cardiopulmonary Disease Diagnostics and Treatment Market Industry. Various countries are implementing policies to enhance healthcare access and promote research in cardiopulmonary health. For instance, increased funding for public health programs and research grants is fostering innovation in diagnostics and treatment methodologies. Such initiatives not only support the development of new technologies but also encourage collaboration between public and private sectors, ultimately contributing to market expansion and improved patient care.

The demographic shift towards an aging population, coupled with lifestyle changes, is a significant driver of the Global Cardiopulmonary Disease Diagnostics and Treatment Market Industry. Older adults are more susceptible to cardiopulmonary diseases, and as life expectancy increases, the demand for effective diagnostics and treatments rises correspondingly. Additionally, lifestyle factors such as sedentary behavior and poor dietary habits contribute to the prevalence of these diseases. This demographic trend underscores the necessity for innovative solutions in diagnostics and treatment, thereby fueling market growth.

The increasing incidence of cardiopulmonary diseases globally is a primary driver for the Global Cardiopulmonary Disease Diagnostics and Treatment Market Industry. Conditions such as chronic obstructive pulmonary disease and heart failure are becoming more prevalent, largely due to aging populations and lifestyle factors. For instance, the World Health Organization indicates that respiratory diseases are among the leading causes of mortality worldwide. This rising prevalence necessitates enhanced diagnostic and treatment solutions, contributing to the market's projected growth from 2.49 USD Billion in 2024 to an estimated 4.72 USD Billion by 2035, reflecting a compound annual growth rate of 5.99% from 2025 to 2035.

Innovations in diagnostic technologies are significantly shaping the Global Cardiopulmonary Disease Diagnostics and Treatment Market Industry. The introduction of advanced imaging techniques, such as high-resolution computed tomography and portable echocardiography devices, enhances the accuracy and efficiency of diagnosing cardiopulmonary conditions. These advancements not only facilitate early detection but also improve patient outcomes. For example, the integration of artificial intelligence in imaging analysis is streamlining the diagnostic process. As these technologies become more accessible, they are likely to drive market growth, aligning with the increasing demand for precise and timely diagnostics.

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American cardiopulmonary disease diagnostics and treatment market area will dominate this market due to the high incidence of cardiovascular diseases, the rapid adoption of minimally invasive procedures, the existence of reimbursements, the growing geriatric population, and the high demand for continuous and home-based monitoring. According to the CDC's most recent statistics, released in October 2022, a heart attack happens in the US every 40 seconds, and over 805,000 people experience one yearly.

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 2  CARDIOPULMONARY DISEASE DIAGNOSTICS AND TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe’s cardiopulmonary disease diagnostics and treatment market accounts for the second-largest market share due, among other things, to a constant increase in the number of patients with CAD and peripheral artery disorders. According to figures made available by the European Union on March 21, 2022, heart attacks were a significant cause of fatalities in the EU. Additionally, technical developments enable portable characteristics in testing equipment, supporting the expansion of the market's revenue.

Further, the German cardiopulmonary disease diagnostics and treatment market held the major market share, and the UK cardiopulmonary disease diagnostics and treatment market was the rapidly growing market in the European region.

The Asia-Pacific Cardiopulmonary Disease Diagnostics and Treatment Market is anticipated to grow quickly from 2024 to 2032. It is due to a high prevalence of heart illnesses in some areas and a sizable patient base needing treatment in nations like China and India. According to a report released by BioSpectrum on June 23, 2022, the number of heart attacks among people under 50 has dramatically grown in China over the past ten years. All age groups, including those under 50, have shown a rise in the age-specific incidence rate of heart attacks per 100,000 persons.

Moreover, China’s cardiopulmonary disease diagnostics and treatment market held the major market share, and the Indian cardiopulmonary disease diagnostics and treatment market was the rapidly growing market in the Asia-Pacific region.

Leading market players are largely investing in research and development to expand their product lines, which will help the cardiopulmonary disease diagnostics and treatment market grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their  presence. The cardiopulmonary disease diagnostics and treatment industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the  cardiopulmonary disease diagnostics and treatment industry to increase market sector and benefits customers is local manufacturing to lower operational costs. In recent years, the cardiopulmonary disease diagnostics and treatment industry has stipulated some of the most important medicinal benefits.  Major players in the cardiopulmonary disease diagnostics and treatment industry, including Cosmed Medical, Cardinal Health, GE Healthcare, Schiller AG, Koninklijke Philips N.V., and others, are funding operations for research and development to boost market demand.

Medtronic plc is a medical device firm based in the United States. The operational and executive headquarters of the corporation are in Minneapolis, Minnesota, and the legal headquarters are in Ireland. Medtronic PLC creates medical products that are both therapeutic and diagnostic. Products for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders are among the company's mainstays.

In October 2022, Medtronic plc received FDA approval for expanded labeling of a cardiac lead that taps into the heart's natural electrical system, providing needed therapy while avoiding complications associated with traditional pacing methods, such as cardiomyopathy. Medtronic was the first and only firm to approve conduction system pacing therapy.

GSK plc, formerly GlaxoSmithKline plc, is a multinational pharmaceutical and biotechnology corporation based in London, England. GSK is one of the major pharmaceutical firms in terms of total sales. The company has clout in various therapeutic areas, including respiratory, cancer, antiviral drugs, and vaccines. GSK employs joint ventures to develop scale in some industries, such as HIV. In April 2022, GlaxoSmithKline Pharmaceuticals Limited introduced Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple treatment (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients on a once-daily basis.

Drugs Controller General of India approved the medicine as a maintenance treatment to prevent and relieve Chronic Obstructive Pulmonary Disease symptoms in patients aged 18 and above.